S1 Biopharma – Investment Overview

TEL: +1 (415) 889-1010


S1 Biopharma


Founded in 2008, S1Biopharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of drugs for the treatment of sexual dysfunction in both women and men. The company’s non-hormonal therapies work by restoring the natural balance of neurotransmitters in the brain.


Nicolas G. Sitchon - Chief Executive Officer
John F. Kaufmann - Chief Financial Officer
Robert E. Pyke - Medical Advisory Board Member, Previous Chief Medical Officer
Anita Clayton - Medical Advisory Board Member

and a representative from US Capital Global Securities will get in touch with you to provide more information on this investment opportunity.



Securities offered through US Capital Global Securities, LLC, member FINRA, SIPC.

IMPORTANT: All investing is risky, and no investor should decide to commit funds without first consulting with a competent professional adviser. Some or all invested funds can be lost. The past performance of any investment, investment strategy or investment style is not indicative of future performance. Future results may vary, and are not guaranteed. The value of investments and their income may increase or decrease, and a loss of principal – including all principal – may occur.

For more investor information or support please call 415-889-1010 or email support@uscgs.com